Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Hay

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Blood|April 8, 2011
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United KingdomCharles R M Hay, Ben Palmer, Elizabeth Chalmers, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 25, 2016
The impact of sport on health status, psychological well-being and physical performance of adults with haemophiliaS von Mackensen, C Harrington, E Tuddenham, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 16, 2009
The mutation spectrum associated with type 3 von Willebrand disease in a cohort of patients from the north west of EnglandM S Sutherland, S Keeney, P H B Bolton-Maggs, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 17, 2017
Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficencyG N Pike, A M Cumming, J Thachil, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 19, 2016
Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiencyG N Pike, A M Cumming, J Thachil, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 5, 2011
Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgeryC R M Hay, A Hellmann, A Dmoszynska, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 17, 2015
Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance studyV Rodriguez, M E Mancuso, D Warad, et al.
BMJ Open|June 2, 2019
Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE studyJohannes Oldenburg, Charles R M Hay, Víctor Jiménez-Yuste, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 14, 2018
The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United KingdomM C Mathias, P W Collins, B P Palmer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 29, 2023
Association of patient, treatment and disease characteristics with patient-reported outcomes: Results of the ECHO RegistryCharles R M Hay, Michael Makris, Midori Shima, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Blood|April 8, 2011
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United KingdomCharles R M Hay, Ben Palmer, Elizabeth Chalmers, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 25, 2016
The impact of sport on health status, psychological well-being and physical performance of adults with haemophiliaS von Mackensen, C Harrington, E Tuddenham, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 16, 2009
The mutation spectrum associated with type 3 von Willebrand disease in a cohort of patients from the north west of EnglandM S Sutherland, S Keeney, P H B Bolton-Maggs, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 17, 2017
Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficencyG N Pike, A M Cumming, J Thachil, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 19, 2016
Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiencyG N Pike, A M Cumming, J Thachil, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 5, 2011
Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgeryC R M Hay, A Hellmann, A Dmoszynska, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 17, 2015
Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance studyV Rodriguez, M E Mancuso, D Warad, et al.
BMJ Open|June 2, 2019
Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE studyJohannes Oldenburg, Charles R M Hay, Víctor Jiménez-Yuste, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 14, 2018
The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United KingdomM C Mathias, P W Collins, B P Palmer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 29, 2023
Association of patient, treatment and disease characteristics with patient-reported outcomes: Results of the ECHO RegistryCharles R M Hay, Michael Makris, Midori Shima, et al.
Pageof 6